[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363137-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363137-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exosome-mediated-delivery-of-mirna-1290-inhibitor-enhances-jnk-dependent-tissue-resident-memory-t-cell-immunity-in-prostate-cancer","Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer","","Prostate cancer remains difficult to treat in advanced stages due to resistance and immune evasion. This study tests whether exosomes carrying a miRNA-1290 inhibitor can improve therapy and reshape immune responses in a prostate cancer mouse model. Exosomes derived from RM-1 cells were loaded with the miRNA-1290 inhibitor and delivered intratumorally to TRAMP mice, with tumor growth, survival, and safety monitored. Single-cell RNA sequencing and flow cytometry characterized intratumoral immune cells, showing enhanced CD8+ tissue-resident memory T cell activity driven by JNK signaling and improved antitumor immunity without evident systemic toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exosome-mediated-delivery-of-mirna-1290-inhibitor-enhances-jnk-dependent-tissue-resident-memory-t-cell-immunity-in-prostate-cancer/363137/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exosome-mediated-delivery-of-mirna-1290-inhibitor-enhances-jnk-dependent-tissue-resident-memory-t-cell-immunity-in-prostate-cancer/363137.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was the miRNA-1290 inhibitor delivered in the study?","Question",{"text":63,"@type":64},"Exosomes derived from RM-1 cells were loaded with the miRNA-1290 inhibitor and administered intratumorally into TRAMP mice.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What outcomes were measured to evaluate therapeutic efficacy?",{"text":68,"@type":64},"Tumor volume, body weight, and overall survival were monitored, and safety was assessed using liver and kidney function tests.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune cells and signaling pathways were implicated by the results?",{"text":72,"@type":64},"Single-cell RNA sequencing and flow cytometry showed increased CD8+ tissue-resident memory T cells, with JNK signaling specifically contributing to reduced IFN-γ and TNF-α production when inhibited.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363137,1790447099,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nExosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer  \nBin Liang & SongnianZou􀀍  \nProstate cancer (PCa) is a leading malignancy in men, particularly challenging in its advanced stages due to treatment resistance and immune evasion. MicroRNA-1290 (miR-1290) was identified tobe implicated in tumor progression, but its role in PCa remains insufficiently characterized. Recent advances in exosome-based delivery systems provide opportunities to target oncogenic miRNAs in vivo. This study aimed to evaluate the therapeutic efficacy and immunomodulatory mechanism of exosome-delivered miR-1290 inhibitor in a PCa mouse model. Exosomes derived from RM-1 cells were loaded with miR-1290 inhibitor and intratumorally administered into TRAMP mice. Tumor volume, body weight, and overall survival were monitored. Safety profiles were evaluated through liver and kidney function tests. Single-cell RNA sequencing (scRNA-seq) and flow cytometry were used to profile intratumoral immune cells, particularly CD8⁺ tissue-resident memory T cells (Trm) . Cytokine levels and MAPK signaling activity were assessed, JNK, ERK, and p38 signaling pathways were selectively inhibited to identify immune mechanisms. MiR-1290 expression was elevated in prostate tumor tissues and was significantly suppressed by exosome-delivered miR-1290 inhibitor. Treated mice exhibited reduced tumor growth, improved body weight, and prolonged survival compared with controls, without evident systemic toxicity. scRNA-seq revealed a marked increase of CD8⁺ Trm cells in the prostate tumor tissues of treated mice, with enrichment of inflammatory and immune response pathways, particularly MAPK signaling. The results of the flow cytometry experiment also indicated a marked increase ofT cells, CD8 T cells, and CD8 Trm cells in the tumor tissues of miR-1290 inhibitor treated mice. Inhibiting JNK, but not ERK or p38, suppressed IFN-γ and TNF-α production by Trm. Exosome-mediated delivery of a miRNA-1290 inhibitor effectively remodels the prostate tumor microenvironment by enhancing JNK-dependent Trm activation, resulting in efficient and durable antitumor immunity. These findings support miRNA-1290 as a promising therapeutic target and highlight exosome-based RNA therapeutics as a novel strategy for prostate cancer management, warranting further translational development.  \nKeywords Prostate cancer, miRNA-1290, exosome, Trm, JNK  \nProstate cancer is one of the most common cancers in males across the globe, accounting for a significant portion of cancer-related morbidity and death. Despite advances in early identification and treatment approaches, metastatic prostate cancer remains a serious issue in terms of therapeutic effectiveness and long-term patient survival1,2. Current therapeutic strategies, including androgen deprivation therapy and chemotherapy, often face limitations such as resistance and adverse side effects, emphasizing the need for novel and more effective therapeutic approaches. Understanding the molecular mechanisms underlying prostate cancer progression is essential for identifying potential targets for treatment3.  \nMiRNAs, small non-coding RNA molecules that regulate gene expression at the post-transcriptional level, have garnered substantial interest in recent years for their roles in cancer biology. MiRNAs modulate a wide array of cellular processes, such as proliferation, apoptosis, and migration, by targeting messenger RNAs (mRNAs)  \nDepartment of Urology, Changzhou Cancer (Fourth People’s) Hospital, Changzhou 213032, China. 􀀍 email: [zuhej3@163.com](zuhej3@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \ninvolved in cancer-related pathways. The dysregulation of miRNA expression has been implicated in numerous cancers, including prostate cancer, where miRNAs may act as oncogenes ","cbCaigD6YjhNO0zp","https://ap.wps.com/l/cbCaigD6YjhNO0zp","pdf",4085669,11,"English","# Background and Rationale\n## Prostate cancer challenges and therapeutic need\n## Roles of miRNAs in cancer biology\n## Exosomes as drug-delivery vehicles\n# Study Design and Delivery Approach\n## Exosome preparation and miRNA-1290 inhibitor loading\n## Mouse model and treatment administration\n## Safety and efficacy monitoring\n# Immunological and Molecular Mechanisms\n## Single-cell RNA sequencing and immune-cell profiling\n## Flow cytometry analysis of T-cell subsets\n## Cytokine production and MAPK pathway involvement\n# Key Findings and Conclusions\n## miRNA-1290 suppression and reduced tumor growth\n## JNK-dependent Trm activation and durable antitumor immunity","[{\"question\":\"How was the miRNA-1290 inhibitor delivered in the study?\",\"answer\":\"Exosomes derived from RM-1 cells were loaded with the miRNA-1290 inhibitor and administered intratumorally into TRAMP mice.\"},{\"question\":\"What outcomes were measured to evaluate therapeutic efficacy?\",\"answer\":\"Tumor volume, body weight, and overall survival were monitored, and safety was assessed using liver and kidney function tests.\"},{\"question\":\"What immune cells and signaling pathways were implicated by the results?\",\"answer\":\"Single-cell RNA sequencing and flow cytometry showed increased CD8+ tissue-resident memory T cells, with JNK signaling specifically contributing to reduced IFN-γ and TNF-α production when inhibited.\"}]","Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer | PDF",1790150125,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0a9060494a8fe7d4dbee763f3d90d2c.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea1297b602cea5c68f0c45e39477b965.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d1db1fa1dfc4a9c09f9c0f5b2585e5d.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05db71c11745df1af6ab5b9484e4a152.webp",980,1287]